S&P 500   3,852.36
DOW   32,920.46
QQQ   296.26
Inflation Tips for Startups – Top 11
The Next Big Crisis Is Here (Ad)
Trustees picked by DeSantis may change progressive college
Qatar replaces Russian company in Lebanon gas exploration
Is This The End of Capitalism? (Ad)
France must raise pension age to 64, prime minister says
Elon Musk's mysterious ways on display in Tesla tweet trial
The Next Big Crisis Is Here (Ad)
Biden, McCarthy to discuss debt limit in talks on Wednesday
Cassava Sciences Stock Undervalued with Its $124 Price Target?
S&P 500   3,852.36
DOW   32,920.46
QQQ   296.26
Inflation Tips for Startups – Top 11
The Next Big Crisis Is Here (Ad)
Trustees picked by DeSantis may change progressive college
Qatar replaces Russian company in Lebanon gas exploration
Is This The End of Capitalism? (Ad)
France must raise pension age to 64, prime minister says
Elon Musk's mysterious ways on display in Tesla tweet trial
The Next Big Crisis Is Here (Ad)
Biden, McCarthy to discuss debt limit in talks on Wednesday
Cassava Sciences Stock Undervalued with Its $124 Price Target?
S&P 500   3,852.36
DOW   32,920.46
QQQ   296.26
Inflation Tips for Startups – Top 11
The Next Big Crisis Is Here (Ad)
Trustees picked by DeSantis may change progressive college
Qatar replaces Russian company in Lebanon gas exploration
Is This The End of Capitalism? (Ad)
France must raise pension age to 64, prime minister says
Elon Musk's mysterious ways on display in Tesla tweet trial
The Next Big Crisis Is Here (Ad)
Biden, McCarthy to discuss debt limit in talks on Wednesday
Cassava Sciences Stock Undervalued with Its $124 Price Target?
S&P 500   3,852.36
DOW   32,920.46
QQQ   296.26
Inflation Tips for Startups – Top 11
The Next Big Crisis Is Here (Ad)
Trustees picked by DeSantis may change progressive college
Qatar replaces Russian company in Lebanon gas exploration
Is This The End of Capitalism? (Ad)
France must raise pension age to 64, prime minister says
Elon Musk's mysterious ways on display in Tesla tweet trial
The Next Big Crisis Is Here (Ad)
Biden, McCarthy to discuss debt limit in talks on Wednesday
Cassava Sciences Stock Undervalued with Its $124 Price Target?
NASDAQ:CNCE

Concert Pharmaceuticals - CNCE Stock Forecast, Price & News

$8.39
+0.06 (+0.72%)
(As of 01/27/2023 08:54 PM ET)
Add
Compare
Today's Range
$8.30
$8.44
50-Day Range
$4.34
$8.39
52-Week Range
$2.57
$8.44
Volume
1.17 million shs
Average Volume
4.45 million shs
Market Capitalization
$402.22 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$19.67

Concert Pharmaceuticals MarketRank™ Forecast

Analyst Rating
Hold
2.20 Rating Score
Upside/​Downside
134.4% Upside
$19.67 Price Target
Short Interest
Healthy
4.53% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-0.93
Upright™ Environmental Score
News Sentiment
0.62mentions of Concert Pharmaceuticals in the last 14 days
Based on 11 Articles This Week
Insider Trading
Selling Shares
$87,872 Sold Last Quarter
Proj. Earnings Growth
Growing
From ($2.70) to ($2.13) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.55 out of 5 stars

Medical Sector

142nd out of 1,049 stocks

Pharmaceutical Preparations Industry

59th out of 514 stocks


CNCE stock logo

About Concert Pharmaceuticals (NASDAQ:CNCE) Stock

Concert Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company, which discovers and develops novel small molecule drugs through the use of deuterium technology. Its product candidates target a range of diseases including autoimmune disorders, inflammation, and central nervous system disorders. The company was founded by Richard H. Aldrich, Roger D. Tung and Christoph H. Westphal on April 12, 2006 and is headquartered in Lexington, MA.

Receive CNCE Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Concert Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

CNCE Stock News Headlines

Is This The End of Capitalism?
EXPOSED: The establishment plot to disenfranchise and impoverish millions of Americans…
StockNews.com Lowers Concert Pharmaceuticals (NASDAQ:CNCE) to Sell
The Next Big Crisis Is Here
You just can’t see it yet because it’s NOT a banking, financial, or economic crisis… it’s far worse and threatens every dollar in your retirement account.
See More Headlines
Receive CNCE Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Concert Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

CNCE Company Calendar

Last Earnings
11/07/2022
Today
1/29/2023
Next Earnings (Estimated)
3/02/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:CNCE
Employees
64
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$19.67
High Stock Price Forecast
$25.00
Low Stock Price Forecast
$17.00
Forecasted Upside/Downside
+134.4%
Consensus Rating
Hold
Rating Score (0-4)
2.20
Research Coverage
5 Analysts

Profitability

Net Income
$-80,050,000.00
Pretax Margin
-300,735.69%

Debt

Sales & Book Value

Annual Sales
$32.58 million
Book Value
$3.24 per share

Miscellaneous

Free Float
42,507,000
Market Cap
$402.22 million
Optionable
Optionable
Beta
0.30

Key Executives

  • Roger D. TungRoger D. Tung
    President, Chief Executive Officer & Director
  • Nancy StuartNancy Stuart
    Chief Operating Officer
  • Marc A. BeckerMarc A. Becker
    Chief Financial & Accounting Officer
  • Mitch K. Goldenberg
    VP-Information Technology & Infrastructure
  • Virginia Braman
    Vice President-Clinical Development













CNCE Stock - Frequently Asked Questions

Should I buy or sell Concert Pharmaceuticals stock right now?

5 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Concert Pharmaceuticals in the last year. There are currently 4 hold ratings and 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" CNCE shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in CNCE, but not buy additional shares or sell existing shares.
View CNCE analyst ratings
or view top-rated stocks.

What is Concert Pharmaceuticals' stock price forecast for 2023?

5 brokerages have issued 1 year target prices for Concert Pharmaceuticals' stock. Their CNCE share price forecasts range from $17.00 to $25.00. On average, they expect the company's share price to reach $19.67 in the next twelve months. This suggests a possible upside of 134.4% from the stock's current price.
View analysts price targets for CNCE
or view top-rated stocks among Wall Street analysts.

How have CNCE shares performed in 2023?

Concert Pharmaceuticals' stock was trading at $5.84 at the beginning of the year. Since then, CNCE shares have increased by 43.7% and is now trading at $8.39.
View the best growth stocks for 2023 here
.

When is Concert Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, March 2nd 2023.
View our CNCE earnings forecast
.

How were Concert Pharmaceuticals' earnings last quarter?

Concert Pharmaceuticals, Inc. (NASDAQ:CNCE) posted its quarterly earnings results on Monday, November, 7th. The biotechnology company reported ($0.58) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.59) by $0.01. The biotechnology company earned $0.01 million during the quarter, compared to analyst estimates of $0.33 million.

What is Roger Tung's approval rating as Concert Pharmaceuticals' CEO?

1 employees have rated Concert Pharmaceuticals Chief Executive Officer Roger Tung on Glassdoor.com. Roger Tung has an approval rating of 100% among the company's employees. This puts Roger Tung in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Concert Pharmaceuticals own?
What is Concert Pharmaceuticals' stock symbol?

Concert Pharmaceuticals trades on the NASDAQ under the ticker symbol "CNCE."

Who are Concert Pharmaceuticals' major shareholders?

Concert Pharmaceuticals' stock is owned by a number of institutional and retail investors. Top institutional shareholders include Assenagon Asset Management S.A. (1.60%). Insiders that own company stock include Heek Christi Van, James V Cassella, Jeffrey A Munsie, Marc A Becker, Nancy Stuart, Peter Barton Hutt, Roger D Tung and Thomas G Auchincloss.
View institutional ownership trends
.

How do I buy shares of Concert Pharmaceuticals?

Shares of CNCE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Concert Pharmaceuticals' stock price today?

One share of CNCE stock can currently be purchased for approximately $8.39.

How much money does Concert Pharmaceuticals make?

Concert Pharmaceuticals (NASDAQ:CNCE) has a market capitalization of $402.22 million and generates $32.58 million in revenue each year. The biotechnology company earns $-80,050,000.00 in net income (profit) each year or ($3.21) on an earnings per share basis.

How can I contact Concert Pharmaceuticals?

Concert Pharmaceuticals' mailing address is 65 HAYDEN AVENUE SUITE 3000N, LEXINGTON MA, 02421. The official website for the company is www.concertpharma.com. The biotechnology company can be reached via phone at (781) 860-0045, via email at ir@concertpharma.com, or via fax at 302-636-5454.

This page (NASDAQ:CNCE) was last updated on 1/30/2023 by MarketBeat.com Staff